Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.19 CAD | -2.56% | -9.52% | +35.71% |
Apr. 19 | Pharmala Biotech Completes $750,000 Private Placement, Debt Settlement | MT |
Apr. 19 | Pharmala Biotech Holdings Inc. announced that it has received CAD 0.75 million in funding | CI |
Business Summary
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Engineering-grade (Non-GMP) Product
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +581.44% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +581.44% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nick Kadysh
CEO | Chief Executive Officer | 38 | 21-03-20 |
Carmelo Marrelli
DFI | Director of Finance/CFO | 53 | 21-03-21 |
Harpreet Kaur
CTO | Chief Tech/Sci/R&D Officer | - | - |
Shane Morris
COO | Chief Operating Officer | 49 | 21-03-21 |
David Purcell
SAM | Sales & Marketing | - | 22-03-13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kevin Roy
BRD | Director/Board Member | - | 22-06-03 |
Director/Board Member | 62 | 21-03-20 | |
Jodi Butts
CHM | Chairman | 51 | 21-03-20 |
Nick Kadysh
CEO | Chief Executive Officer | 38 | 21-03-20 |
Perry Tsergas
BRD | Director/Board Member | 39 | 21-03-20 |
Fraser MacDonald
BRD | Director/Board Member | 38 | 21-03-20 |
Harriet de Wit
BRD | Director/Board Member | 76 | 21-03-20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 86,907,552 | 81,657,052 ( 93.96 %) | 0 | 93.96 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+35.71% | 12.32M | |
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- MDMA Stock
- Company Pharmala Biotech Holdings Inc.